Comparing Efficacy and Safety of TJO-083 in Dry Eye Diseases Patients

Launched by TAEJOON PHARMACEUTICAL CO., LTD. · May 19, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new medication called TJO-083 to see how well it works for patients suffering from dry eye syndrome. Over a period of 12 weeks, participants will receive either TJO-083 or a standard control medication, and doctors will assess the health of their eyes by checking for any staining on the cornea, which is the clear front part of the eye. The goal is to determine if TJO-083 is at least as effective as the control medication in relieving dry eye symptoms.

To participate in this study, individuals must be at least 20 years old and have experienced dry eye symptoms for at least three months. Participants will also need to be able to see clearly enough during a vision test. However, those who have recently used certain eye treatments, have specific eye or overall health issues, or have elevated eye pressure may not be eligible. If you join this trial, you’ll receive close monitoring from healthcare professionals and contribute to important research that could help improve treatments for dry eye syndrome.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male or female, age 20 or over
• • Has dry eye symptoms (minimum 3 months)
• • Screening both eyes, the corrected visual acuity is 0.2 or more
• • Written informed consent to participate in the trial
• Exclusion Criteria:
• • The patients who treated with topical NSAIDs/hyaluronate sodium ophthalmic solutions within 2 weeks of randomized visits.
• • The patients with systemic or ocular disorders affecting the test results(ocular surgery, trauma, or disease) within 2 months of screening visits.
• • Intraocular pressure(IOP)\> 21 mmHg
• • Patients with contact lens